• 
  C.S. Groeneveld, C. Pfister, S. Culine, V. Harter, C. Krucker, et al.. Basal/squamous and Mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial. Annals of Oncology, 2024, ⟨10.1016/j.annonc.2024.09.008⟩. ⟨hal-04780573⟩
• 
  V. Camus, R. Houot, G. Brisou, B. Tessoulin, S. Bailly, et al.. Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells.. Blood Advances, 2024, 8 (20), pp.5371-5381. ⟨10.1182/bloodadvances.2024013726⟩. ⟨hal-04708799⟩
• 
  Riccardo Rigo, Rabie Chelbi, Julie Agopian, Sebastien Letard, Aurélien Griffon, et al.. TET2 regulates immune tolerance in chronically activated mast cells. JCI Insight, 2022, 7 (7), ⟨10.1172/jci.insight.154191⟩. ⟨hal-04772652⟩
• 
  Olivier Bylicki, Florian Guisier, Arnaud Scherpereel, Catherine Daniel, Aurélie Swalduz, et al.. Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial. Lung Cancer, 2024, 194, pp.107866. ⟨10.1016/j.lungcan.2024.107866⟩. ⟨hal-04751314⟩
• 
  Francois Gouin, Audrey Michot, Mehrdad Jafari, Charles Honoré, Jean Camille Mattei, et al.. Improved metastatic-free survival after systematic re-excision following complete macroscopic unplanned excision of limb or trunk soft tissue sarcoma. Cancers, 2024, 16 (7), pp.1365. ⟨10.3390/cancers16071365⟩. ⟨hal-04653665⟩
• 
  Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, et al.. Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nature Medicine, 2023, 29 (10), pp.2665-2665. ⟨10.1038/s41591-023-02624-w⟩. ⟨hal-04755672⟩
• 
  Stéphane J.C. Mancini, Karl Balabanian, Isabelle Corre, Julie Gavard, Gwendal Lazennec, et al.. Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies. Frontiers in Immunology, 2021, 12, pp.766275. ⟨10.3389/fimmu.2021.766275⟩. ⟨hal-04673450⟩
• 
  Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, et al.. Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nature Medicine, 2024, 30 (7), pp.2089 - 2089. ⟨10.1038/s41591-024-03053-z⟩. ⟨hal-04753011⟩
• 
  Nadège Baldeck, Régine Janel-Bintz, Jérome Wagner, Agnès Tissier, Robert Fuchs, et al.. FF_483–484 motif of human Polη mediates its interaction with the POLD2 subunit of Polδ and contributes to DNA damage tolerance. Nucleic Acids Research, 2016, 43 (4), pp.2116-2125. ⟨10.1093/nar/gkv076⟩. ⟨hal-03300649⟩
• 
  Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
• 
  Léa Montégut, Peng Liu, Liwei Zhao, María Pérez-Lanzón, Hui Chen, et al.. Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance. Molecular Cancer, 2024, 23 (1), pp.187. ⟨10.1186/s12943-024-02098-5⟩. ⟨hal-04704596⟩
• 
  Lucillia Bezu, Alejandra Wu Chuang, Allan Sauvat, Juliette Humeau, Wei Xie, et al.. Local anesthetics elicit immune-dependent anticancer effects. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (4), ⟨10.1136/jitc-2021-004151⟩. ⟨hal-04085321⟩
• 
  Timothy Rebbeck, Tara Friebel, Eitan Friedman, Ute Hamann, Dezheng Huo, et al.. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Human Mutation, 2018, 39 (5), pp.593-620. ⟨10.1002/humu.23406⟩. ⟨hal-02351570⟩
• 
  F. Pommeret, J. Colomba, C. Bigenwald, A. Laparra, S. Bockel, et al.. Bamlanivimab + Etesevimab Therapy Induces SARS-CoV-2 Immune Escape Mutations and Secondary Clinical Deterioration in COVID-19 Patients with B-cell Malignancies. Annals of Oncology, 2021, 32 (11), pp.1445--1447. ⟨10.1016/j.annonc.2021.07.015⟩. ⟨hal-03793520⟩
• 
  Charles Herbaux, Caroline Bret, Emmanuel Bachy, Pierre Bories, Roberta Di Blasi, et al.. Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.. Haematologica, 2024, Haematologica, ⟨10.3324/haematol.2023.284786⟩. ⟨hal-04689105⟩
• 
  Claire Michel, Marie Robin, Stephane Morisset, Didier Blaise, Johan Maertens, et al.. Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS. Bone Marrow Transplantation, 2023, Bone Marrow Transplantation, 58 (5), pp.534-543. ⟨10.1038/s41409-023-01931-7⟩. ⟨hal-04672661⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.. Lancet Oncology, 2022, Lancet Oncology, 23 (8), pp.1044-1054. ⟨10.1016/S1470-2045(22)00380-1⟩. ⟨hal-04387055⟩
• 
  Hélène Tubeuf, Sandrine M Caputo, Teresa Sullivan, Julie Rondeaux, Sophie Krieger, et al.. Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System. Cancer Research, 2020, 80 (17), pp.3593-3605. ⟨10.1158/0008-5472.CAN-20-0895⟩. ⟨hal-03597164⟩
• 
  Justin Loke, Myriam Labopin, Charles Craddock, Gérard Socié, Tobias Gedde-Dahl, et al.. Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study.. Cancer, 2024, Cancer, 130, pp.2642-2651. ⟨10.1002/cncr.35308⟩. ⟨hal-04672868⟩
• 
  Guy Gorochov, Jacques Ropers, Odile Launay, Karim Dorgham, Omaira da Mata-Jardin, et al.. Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination. JAMA Network Open, 2024, 7 (4), pp.e248051. ⟨10.1001/jamanetworkopen.2024.8051⟩. ⟨hal-04669127⟩

371

374